Custodiol - N versus Custodiol: a prospective randomized double blind multicenter phase III Trial

Journal of Cardiothoracic Surgery ◽

10.1186/1749-8090-10-s1-a73 ◽

2015 ◽

Vol 10 (S1) ◽

Author(s):

Gábor Szabó ◽

Alexander Weymann ◽

Bastian Schmack ◽

Dominika Badowsky-Zyla ◽

Gábor Gábor Veres ◽

...

Keyword(s):

Phase Iii ◽

Double Blind ◽

Phase Iii Trial ◽

Multicenter Phase

Download Full-text

Custodiol-N versus custodiol: A prospective randomized double blind multicenter phase III trial

The Thoracic and Cardiovascular Surgeon ◽

10.1055/s-0034-1367380 ◽

2014 ◽

Vol 62 (S 01) ◽

Author(s):

G. Szabó ◽

A. Weymann ◽

B. Schmack ◽

D. Badowsky-Zyla ◽

G. Veres ◽

...

Keyword(s):

Phase Iii ◽

Double Blind ◽

Phase Iii Trial ◽

Multicenter Phase

Download Full-text

Updated Results from the Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Trial (RADIANT-3) of Everolimus in Patients with Advanced Pancreatic Neuroendocrine Tumors (pNET)

The American Journal of Gastroenterology ◽

10.14309/00000434-201110002-00145 ◽

2011 ◽

Vol 106 ◽

pp. S59 ◽

Author(s):

Edward Wolin ◽

Rodney Pommier ◽

Jeremie Lincy ◽

Robert Winkler ◽

James Yao

Keyword(s):

Neuroendocrine Tumors ◽

Phase Iii ◽

Pancreatic Neuroendocrine Tumors ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

Multicenter Phase

Download Full-text

A randomized, double-blind, placebo (P) controlled, multicenter phase III trial to evaluate the efficacy and safety of adding bevacizumab (B) to erlotinib (E) and gemcitabine (G) in patients (pts) with metastatic pancreatic cancer

Journal of Clinical Oncology ◽

10.1200/jco.2008.26.15_suppl.4507 ◽

2008 ◽

Vol 26 (15_suppl) ◽

pp. 4507-4507 ◽

Author(s):

W. Vervenne ◽

J. Bennouna ◽

Y. Humblet ◽

S. Gill ◽

M. J. Moore ◽

...

Keyword(s):

Pancreatic Cancer ◽

Phase Iii ◽

Metastatic Pancreatic Cancer ◽

Efficacy And Safety ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

Multicenter Phase

Download Full-text

Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: A randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients

Critical Care Medicine ◽

10.1097/00003246-200103000-00006 ◽

2001 ◽

Vol 29 (3) ◽

pp. 503-510 ◽

Author(s):

Edward Abraham ◽

Pierre-François Laterre ◽

Jorge Garbino ◽

Susan Pingleton ◽

Thomas Butler ◽

...

Keyword(s):

Septic Shock ◽

Severe Sepsis ◽

Tumor Necrosis ◽

Tumor Necrosis Factor Receptor ◽

Phase Iii ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

Multicenter Phase ◽

Necrosis Factor

Download Full-text

Efficacy and Safety of Morning Versus Evening Dose of Controlled-Release Simvastatin Tablets in Patients With Hyperlipidemia: A Randomized, Double-Blind, Multicenter Phase III Trial

Clinical Therapeutics ◽

10.1016/j.clinthera.2013.06.020 ◽

2013 ◽

Vol 35 (9) ◽

pp. 1350-1360.e1 ◽

Author(s):

Sang-Hyun Kim ◽

Min-Kyung Kim ◽

Hong-Seok Seo ◽

Min-Soo Hyun ◽

Kyoo-Rok Han ◽

...

Keyword(s):

Controlled Release ◽

Phase Iii ◽

Efficacy And Safety ◽

Double Blind ◽

Evening Dose ◽

Phase Iii Trial ◽

Multicenter Phase

Download Full-text

Everolimus in patients with advanced pancreatic neuroendocrine tumors (pNET): Updated results of a randomized, double-blind, placebo-controlled, multicenter, phase III trial (RADIANT-3).

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.4009 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. 4009-4009 ◽

Author(s):

J. R. Strosberg ◽

J. Lincy ◽

R. E. Winkler ◽

E. M. Wolin

Keyword(s):

Neuroendocrine Tumors ◽

Phase Iii ◽

Pancreatic Neuroendocrine Tumors ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

Multicenter Phase

Download Full-text

6566 POSTER Updated Safety and Efficacy Results From RADIANT-2 – a Randomized, Double-blind, Multicenter, Phase III Trial of Everolimus + Octreotide LAR Vs Placebo + Octreotide LAR in Pts With Advanced Neuroendocrine Tumours (NET)

European Journal of Cancer ◽

10.1016/s0959-8049(11)71877-9 ◽

2011 ◽

Vol 47 ◽

pp. S461

Author(s):

S. Ricci ◽

P. Ruszniewski ◽

P. Tomasetti ◽

V. Jehl ◽

S. Saletan ◽

...

Keyword(s):

Neuroendocrine Tumours ◽

Phase Iii ◽

Double Blind ◽

Phase Iii Trial ◽

Safety And Efficacy ◽

Octreotide Lar ◽

Multicenter Phase

Download Full-text

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trial of Everolimus + Octreotide LARvs.Placebo + Octreotide LAR in Patients with Advanced Neuroendocrine Tumors (NET) (RADIANT-2): Updated Safety Results

10.1210/endo-meetings.2011.part3.or6.or25-1 ◽

2011 ◽

pp. OR25-1-OR25-1

Author(s):

David Gross ◽

Marc Peeters ◽

Valentine Jehl ◽

Stephen Saletan ◽

Lucas Sideris

Keyword(s):

Neuroendocrine Tumors ◽

Phase Iii ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

Octreotide Lar ◽

Multicenter Phase

Download Full-text

96O Camrelizumab or placebo plus carboplatin and paclitaxel as first-line treatment for advanced squamous NSCLC (CameL-sq): A randomized, double-blind, multicenter, phase III trial

Journal of Thoracic Oncology ◽

10.1016/s1556-0864(21)01938-9 ◽

2021 ◽

Vol 16 (4) ◽

pp. S748

Author(s):

C. Zhou ◽

S. Ren ◽

J. Chen ◽

X. Xu ◽

Y. Cheng ◽

...

Keyword(s):

Phase Iii ◽

Line Treatment ◽

Double Blind ◽

Phase Iii Trial ◽

Multicenter Phase ◽

First Line Treatment

Download Full-text

Everolimus (Eve) for the Treatment of Advanced Pancreatic Neuroendocrine Tumors (Pnet): Final Overall Survival (Os) Results of a Randomized, Double-Blind, Placebo (Pbo)-Controlled, Multicenter Phase III Trial (Radiant-3)

Annals of Oncology ◽

10.1093/annonc/mdu345.1 ◽

2014 ◽

Vol 25 ◽

pp. iv394 ◽

Author(s):

J.C. Yao ◽

M. Pavel ◽

C. Lombard-Bohas ◽

E. van Cutsem ◽

D. Lam ◽

...

Keyword(s):

Overall Survival ◽

Neuroendocrine Tumors ◽

Phase Iii ◽

Pancreatic Neuroendocrine Tumors ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

Multicenter Phase

Download Full-text